Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,563.63
(
0.58%
)
US TECH 100
29,441.20
(
0.90%
)
Dow Jones
50,668.97
(
0.05%
)
Brent Oil
92.60
(
0.17%
)
Bitcoin
73,546.98
(
-1.79%
)
News Focus
News Focus
Post# of 448117
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

roadkilll

Send PM Follow Ignore
Followers 7
Posts 739
Boards Moderated 0
Alias Born 08/25/2012

roadkilll

Re: roadkilll post# 432358

Wednesday, 01/15/2025 7:16:02 PM

Wednesday, January 15, 2025 7:16:02 PM

Post# of 448117
HLS Therapeutics in Canada has the rights to Vascepa.
Q3 results - Vascepa revenue in Canada increased 30% in constant currency compared to Q3 2023 versus Q3 2024
Vascepa unit demand increased by 45% compared to Q3 2023.
The number of consistent prescribers2 for Vascepa increased 66% compared to Q3 2023.
.
This small company is about to turn cash flow positive on Vascepa related revenues/cost. Amarin????
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AMRN News
More AMRN News